Current management of benign retroperitoneal tumors
Fabio Tirotta(University Hospitals Birmingham NHS Foundation Trust), William W. Tseng(Brigham and Women's Hospital), Dakshesh B. Patel(University of Southern California), Erika Schmitz(University of Ottawa), Myles Smith(Royal Marsden NHS Foundation Trust), Samuel Ford(University Hospitals Birmingham NHS Foundation Trust), Khin Thway(Royal Marsden Hospital), Jos A. van der Hage(Leiden University Medical Center), Carolyn Nessim(University of Ottawa), Andrea Napolitano(National Health Service), Sangkyu Noh(UC San Diego Health System), Jason K. Sicklick(University of California San Diego)
Cited by 9
Related Papers
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
|Nature Medicine|2019|710
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
|Cancer Cell|2018|591
Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group
|Annals of Surgical Oncology|2021|251
Elective Cancer Surgery in COVID-19–Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study
|Journal of Clinical Oncology|2020|223